sequencing-based diagnostics
Adaptive Bio Initiates Strategic Review, Considers Separation of MRD, Immune Medicine Businesses
Premium
While reporting its Q3 earnings results, Adaptive said it hired Goldman Sachs to perform "a review of strategic alternatives" for its MRD and immune medicine businesses.
Pacific Biosciences, GeneDx, UW Collaborate on Google-Funded Study of WGS in Neonatal Care
Google will contribute expertise on informatics methods and provide an undisclosed amount of funding, including for reagents, to the project.
Adaptive Biotechnologies Sees ClonoSeq Test Volume Grow, Reports 12 Percent Revenue Growth for Q2
During the quarter, the Seattle-based company reported total revenues of $48.9 million, beating analysts' consensus estimate of $44.9 million.
Adaptive Biotechnologies Q1 Revenues Decline 3 Percent
The Seattle-based immune sequencing firm booked $37.6 million in revenues, with 43 percent from immune medicine and 57 percent from its minimal residual disease business.
Adaptive Biotechnologies Lays out Strategy to Drive ClonoSeq Adoption
The Seattle-based immune sequencing firm reported a 46 percent increase in fourth quarter revenues, about equally split between its MRD and immune medicine businesses.